A virtual workshop in November 2022 highlighted the importance of developing mucosal vaccines for SARS-CoV-2 that could reduce transmission and infection. Participants discussed challenges and priorities, such as identifying protection correlates, improving animal models, and determining delivery methods. Though no COVID-19 mucosal vaccines have been authorized in the US or Europe, the workshop concluded that research in this area could yield benefits for both COVID-19 and other diseases.
In November 2022, the National Institute of Allergy and Infectious Diseases (NIAID) co-hosted a virtual workshop on the importance and challenges of developing mucosal vaccines for SARS-COV-2. The highlights of this workshop have now been published as a report in npj Vaccines.
Although vaccines currently available for COVID-19 are usually effective at preventing severe disease, hospitalizations and death, researchers recognize the need for improvement. A vaccine more effective at preventing transmission or infection with SARS-CoV-2 could reduce overall replication of the virus and associated disease burden. Because SARS-CoV-2 enters the body and is transmitted via the respiratory tract, a vaccine to promote a mucosal immune response in the respiratory tract could be better at blocking transmission and infection. Although at least 44 mucosal vaccines are currently in preclinical development, and several more are in clinical development or authorized for use in other countries, no COVID-19 mucosal vaccines have been authorized for use by regulatory agencies in the United States or Europe.
For instance, new correlates of protection must be identified and verified to evaluate whether a vaccine improves recipients' mucosal immune responses to SARS-CoV-2, and to facilitate clinical testing and regulatory approval. Improved animal models are needed to help researchers develop potential mucosal vaccines, according to the report. Careful clinical design is needed to assess the unique safety concerns related to mucosal vaccines and to appropriately evaluate whether a vaccine can block transmission of the virus. Trial design also needs to account for how vaccines will be used. Since most people have either received a SARS-CoV-2 vaccine or had a natural infection, mucosal vaccines likely will be used as boosters, and researchers will need to know how well vaccines function in people who have some prior immunity. The means of delivery also must be considered: nasal sprays, pills, liquids taken by mouth, and even nebulizers could deliver a vaccine more directly to the respiratory system, but each of these poses unique challenges to manufacture, test and deliver.
Despite these and other challenges, attendees of the workshop were optimistic about the future of mucosal vaccines for COVID-19. Considering the potential benefits that a successful candidate could bring, they concluded that research needed to further mucosal vaccine development is a priority. Such research also could even lead to improved vaccines for other diseases, such as influenza, respiratory syncytial virus (RSV) or tuberculosis, in addition to advancing COVID-19 vaccinology.
News
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]
3D Human Brain Tissue Model Replicates Alzheimer’s Pathology
Summary: Researchers introduced a highly reproducible three-dimensional human brain tissue model capable of replicating complex neurodegenerative processes in Alzheimer’s disease. Developed over nine years using human stem cells, the self-organizing tissue spheroids integrate functional neurons, [...]
A Common Sugar May Loosen Cancer Cells and Help Them Spread
Chemotherapy may kill most ovarian cancer cells, but the few that survive can turn dangerously active. By releasing fructose, they may help nearby tumor cells break free and spread. Researchers at The Wistar Institute [...]
COVID-19 can wake up dormant viruses in the body, large study confirms
Virus reactivations by SARS-CoV-2 could worsen initial symptoms and increase risk of Long Covid. Early in the COVID-19 pandemic, scientists noticed that a SARS-CoV-2 infection can “wake up” other, dormant viruses already present in [...]
Scientists Discover the Brain May Enter a New Biological Phase Between 50 and 75
A single-cell study reveals major changes in immune cells, genome organization, and gene regulation within the aging human hippocampus, offering important insights into brain aging and dementias associated with age. Between roughly ages 50 [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Unzipping the Code of Life: Scientists Pinpoint Where DNA First Opens
Researchers mapped where DNA first opens and how a helicase gate may release one strand as genome copying begins. Before a cell can divide, it must open its tightly wound DNA and begin copying the entire [...]
